Treatment of atrial fibrillation
Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is 4-methoxy-N-(3,5-bis(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide (sulcardine) or a pharmaceutically acceptable salt thereof, such that the Cmax value the active agent in the subject is in the range from about 1 μM to about 20 μM.
1. A method of treating atrial fibrillation (AF), comprising administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent that is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide or a pharmaceutically acceptable salt thereof, such that the maximum steady state plasma concentration (Cmax) of said active agent in said subject is in the range from about 1 μM to about 20 μM.
2. The method according to claim 1 , wherein said Cmax is in the range from about 2 μM to about 10 μM.
3. The method according to claim 1 , wherein the amount of said active agent is in the range from about 3 mg/kg to about 30 mg/kg.
4. The method according to claim 3 , wherein the amount of said active agent is in the range from about 5 mg/kg to about 10 mg/kg.
5. The method according to claim 1 , wherein said active agent is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide sulfate.
6. The method according to claim 1 , wherein said composition further comprises a pharmaceutically acceptable excipient.
7. The method according to claim 6 , wherein said pharmaceutically acceptable excipient is selected from the group consisting of a buffer, a diluent, a stabilizer and combinations thereof.
8. The method according to claim 1 , wherein said administering is by means of intramuscular injection, intravenous injection, subcutaneous injection, or oral, transdermal, inhalation, rectal, sublingual, buccal, intravaginal or nasal administration.
9. The method according claim 2 , wherein said active agent is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide sulfate.
10. The method according claim 3 , wherein said active agent is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide sulfate.
11. The method according claim 4 , wherein said active agent is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide sulfate.
12. The method according to claim 2 , wherein said composition further comprises a pharmaceutically acceptable excipient.
13. The method according to claim 3 , wherein said composition further comprises a pharmaceutically acceptable excipient.
14. The method according to claim 4 , wherein said composition further comprises a pharmaceutically acceptable excipient.